We are live on ! Find out more
MRNS

Marinus Pharmaceuticals, Inc

Delisted

MRNS was delisted on the 10th of February, 2025.

38 hedge funds and large institutions have $54.3M invested in Marinus Pharmaceuticals, Inc in 2015 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

550% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 2

41% more funds holding

Funds holding: 2738 (+11)

38% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 8

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

26% less capital invested

Capital invested by funds: $73.2M → $54.3M (-$18.9M)

Holders
38
Holders Change
+11
Holders Change %
+40.74%
% of All Funds
1.06%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
13
Increased
11
Reduced
8
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CPV
1
Canaan Partners VII
Connecticut
$20.5M
Franklin Resources
2
Franklin Resources
California
$9.1M -$2.98M -52,800 -16%
NLVP
3
New Leaf Venture Partners
New York
$5.88M +$721K +12,769 +8%
PI
4
Putnam Investments
Massachusetts
$2.5M
ACH
5
ArrowMark Colorado Holdings
Colorado
$2.27M +$847K +15,014 +28%
Point72 Asset Management
6
Point72 Asset Management
Connecticut
$1.93M -$43.8K -776 -1%
BBA
7
Baker Bros. Advisors
New York
$1.67M
EA
8
Emerald Advisers
Pennsylvania
$1.57M +$43.2K +765 +2%
SFM
9
Sphera Funds Management
Israel
$1.35M -$1.92M -34,103 -46%
AIC
10
AWM Investment Company
New York
$1.02M -$247K -4,375 -13%
CS
11
Credit Suisse
Switzerland
$826K +$1.09M +19,317 +355%
Allianz Asset Management
12
Allianz Asset Management
Germany
$679K +$1.15M +20,352 New
Goldman Sachs
13
Goldman Sachs
New York
$641K -$413K -7,327 -28%
IHM
14
Iguana Healthcare Management
New York
$626K +$1.06M +18,750 New
Morgan Stanley
15
Morgan Stanley
New York
$569K +$729K +12,914 +312%
PAI
16
Palo Alto Investors
California
$492K +$833K +14,754 New
Vanguard Group
17
Vanguard Group
Pennsylvania
$463K +$322K +5,705 +70%
BCM
18
Bridgeway Capital Management
Texas
$354K +$176K +3,125 +42%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$315K +$19.9K +353 +4%
HCM
20
Harvey Capital Management
Florida
$212K +$148K +2,625 +70%
TC
21
TFS Capital
Pennsylvania
$205K +$97.5K +1,728 +39%
NI
22
Numeric Investors
Massachusetts
$197K +$333K +5,907 New
DCM
23
DAFNA Capital Management
California
$186K
MC
24
Menta Capital
California
$171K +$290K +5,140 New
ARTA
25
A.R.T. Advisors
New York
$169K +$52.6K +932 +22%

MRNS Hedge Fund Activity: Q3 2015 in Review

38 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q3 2015, worth a combined $54.3M — down 26% from $73.2M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new MRNS positions and 2 closed out — a net gain of 11 holders — while 11 added to existing stakes and 8 trimmed.

The largest buyer was Allianz Asset Management, opening a new position worth an estimated $1.15M. The largest seller was Franklin Resources, cutting an estimated $2.98M.

  • 38 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q3 2015, up from 27 in Q2 2015.
  • Funds reported $54.3M of Marinus Pharmaceuticals, Inc stock for Q3 2015, down 26% quarter-over-quarter.
  • 13 funds opened new Marinus Pharmaceuticals, Inc positions in Q3 2015 and 2 closed out, a net change of +11 holders.
  • The largest Marinus Pharmaceuticals, Inc buyer in Q3 2015 was Allianz Asset Management, an estimated $1.15M added.
  • The largest Marinus Pharmaceuticals, Inc seller in Q3 2015 was Franklin Resources, an estimated $2.98M sold.

Based on aggregated 13F filings for Q3 2015.